New drug duo takes aim at Treatment-Resistant prostate cancer

NCT ID NCT07206056

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new combination of two drugs, tulmimetostat and JSB462, is safe and works better than current standard treatments for advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part of the study will find the safest dose, and the second part will compare how well the drug combo controls the cancer versus standard care. It is for adult men whose cancer has progressed after prior treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109-1024, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Novartis Investigative Site
RECRUITING

St Leonards, New South Wales, 2065, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site
RECRUITING

Liverpool, 2170, Australia
Novartis Investigative Site
RECRUITING

Beijing, 100021, China
Novartis Investigative Site
RECRUITING

Vejle, DK-7100, Denmark
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Paris, 75015, France
Novartis Investigative Site
RECRUITING

Milan, MI, 20133, Italy
Novartis Investigative Site
RECRUITING

Kuching, Sarawak, 93586, Malaysia
Novartis Investigative Site
RECRUITING

Poznan, 60-192, Poland
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore
Novartis Investigative Site
RECRUITING

Singapore, S308433, Singapore
Novartis Investigative Site
RECRUITING

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28041, Spain
Sarah Cannon Research Institute
RECRUITING

Denver, Colorado, 80218, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sarah Cannon Research Institute
RECRUITING

Jacksonville, Florida, 32256, United States

Contact Email: •••••@•••••

Contact
Wichita Urology Group PA
RECRUITING

Wichita, Kansas, 67226, United States

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER